July 1, 2014
Albany, NY

Influenza Vaccine Update, CL 803

CL-803: Influenza Vaccine Update
Please address inquiries to:

State Agencies & Contractors

Shrilata Nath Contract Management Specialist (518) 474-4680 [email protected]

Other Authorized Users

Customer Services (518) 474-6717 [email protected]


To all state agencies and others authorized to use state contracts:

Glaxo Smith Kline (GSK) announced that it received an FDA warning related to a routine inspection of one of its facilities manufacturing flu vaccine. GSK states that there may be a potential impact to the supply of FluLaval (influenza vaccine) trivalent formulation (NDC# 19515-893-07) for the 2014-2015 flu season. Currently, GSK does not believe that Flulaval (influenza vaccine) Quadrivalent prefilled syringes or multidose vials (manufactured at the same facility) are affected. Fluarix (influenza vaccine) Quadrivalent is not affected as it is manufactured in a different facility. GSK has changed the status of its flu vaccines to “waitlist”.

There are several influenza vaccine formulations and manufacturers/distributors available. Please compare available contract pricing and follow applicable laws and your agency’s purchasing guidelines.

There is currently an influenza vaccine contract with Sanofi Pasteur, Inc.: 10200-22555 http://www.ogs.ny.gov/purchase/spg/awards/1020022555CAN.HTM

Flu vaccine is also available through the Pharmaceutical Prime Vendor Contract with Cardinal Health: 10200-22000 http://www.ogs.ny.gov/purchase/spg/awards/1020022000CAN.HTM

There are three more influenza vaccine contracts being finalized with FFF Enterprises, Inc., McKesson-Medical Surgical MN Supply, Inc., and Novartis Vaccines & Diagnostics.

If you have questions please contact the Contract Management Specialist listed above.

Download the Announcement